GT Biopharma, Inc.
GTBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000109657
No open-market purchases or sales by GT Biopharma, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $1.02M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in GT Biopharma, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- −17 vs. Q4 2023
- Shares held
- 75.5K
- −39.1K (−34.1%) vs. Q4 2023Converted for a 1-for-30 split
- Total value
- $348.6K
- −$544.5K (−61.0%) vs. Q4 2023
- New holders
- 2
- 3 more added
- Sold out
- 19
- 8 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GTBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $1.02M |
| Q1 2026 | 42 | $656.7K |
| Q4 2025 | 38 | $373.7K |
| Q3 2025 | 21 | $222.2K |
| Q2 2025 | 21 | $711.3K |
| Q1 2025 | 20 | $220.5K |
| Q4 2024 | 19 | $279.1K |
| Q3 2024 | 16 | $203.8K |
| Q2 2024 | 17 | $296.8K |
| Q1 2024 | 17 | $348.6K |
| Q4 2023 | 34 | $893.1K |
| Q3 2023 | 33 | $849.9K |
| Q2 2023 | 37 | $1.11M |
| Q1 2023 | 36 | $3.05M |
| Q4 2022 | 36 | $5.62M |
| Q3 2022 | 35 | $4.36M |
| Q2 2022 | 48 | $9.28M |
| Q1 2022 | 58 | $12.9M |
| Q4 2021 | 55 | $16.7M |
| Q3 2021 | 54 | $32.1M |
| Q2 2021 | 50 | $69.9M |
| Q1 2021 | 21 | $3.98M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding GT Biopharma, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of Montreal | 19,872 | $102.1K | 0.00% | 00.0% | UnchangedConverted for a 1-for-30 split |
| Vanguard Group Inc | 20,512 | $90.9K | 0.00% | −15,754−43.4% | ReducedConverted for a 1-for-30 split |
| Geode Capital Management, LLC | 11,184 | $49.8K | 0.00% | −60−0.5% | ReducedConverted for a 1-for-30 split |
| BlackRock Inc. | 10,132 | $44.9K | 0.00% | 00.0% | UnchangedConverted for a 1-for-30 split |
| Wells Fargo & Company | 10,024 | $44.4K | 0.00% | 00.0% | UnchangedConverted for a 1-for-30 split |
| Tower Research Capital LLC (TRC) | 2,301 | $10.2K | 0.00% | +1,642+249.1% | AddedConverted for a 1-for-30 split |
| UBS Group AG | 1,023 | $4.53K | 0.00% | +536+110.1% | AddedConverted for a 1-for-30 split |
| Morgan Stanley | 266 | $1.18K | 0.00% | −3−1.2% | ReducedConverted for a 1-for-30 split |
| FMR LLC | 61 | $271 | 0.00% | +61 | New |
| Advisor Group Holdings, Inc. | 32 | $142 | 0.00% | −2−5.6% | ReducedConverted for a 1-for-30 split |
| Bank of America Corp | 17 | $75 | 0.00% | −19−52.5% | ReducedConverted for a 1-for-30 split |
| Blue Bell Private Wealth Management, LLC | 10 | $44 | 0.00% | 00.0% | UnchangedConverted for a 1-for-30 split |
| BNP Paribas Arbitrage, SA | 6 | $27 | 0.00% | +6 | New |
| Front Row Advisors LLC | 1 | $4 | 0.00% | −1−48.3% | ReducedConverted for a 1-for-30 split |
| Retirement Group, LLC | 1 | $4 | 0.00% | −0−31.8% | ReducedConverted for a 1-for-30 split |
| JPMorgan Chase & Co | 1 | $4 | 0.00% | +0+87.5% | AddedConverted for a 1-for-30 split |
| Royal Bank of Canada | 7 | $0 | 0.00% | −66−90.4% | ReducedConverted for a 1-for-30 split |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −3,823−100.0% | Sold outConverted for a 1-for-30 split |
| Atria Wealth Solutions, Inc. | 0 | $0 | 0.00% | −3,291−100.0% | Sold outConverted for a 1-for-30 split |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −3,175−100.0% | Sold outConverted for a 1-for-30 split |
| State Street Corp | 0 | $0 | 0.00% | −2,666−100.0% | Sold outConverted for a 1-for-30 split |
| Millennium Management LLC | 0 | $0 | 0.00% | −2,198−100.0% | Sold outConverted for a 1-for-30 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −1,927−100.0% | Sold outConverted for a 1-for-30 split |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −1,239−100.0% | Sold outConverted for a 1-for-30 split |
| LPL Financial LLC | 0 | $0 | 0.00% | −1,144−100.0% | Sold outConverted for a 1-for-30 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −1,078−100.0% | Sold outConverted for a 1-for-30 split |
| HRT Financial LP | 0 | $0 | 0.00% | −1,126−100.0% | Sold outConverted for a 1-for-30 split |
| Marex Group plc | 0 | $0 | 0.00% | −1,000−100.0% | Sold outConverted for a 1-for-30 split |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −762−100.0% | Sold outConverted for a 1-for-30 split |
| Moss Adams Wealth Advisors LLC | 0 | $0 | 0.00% | −667−100.0% | Sold outConverted for a 1-for-30 split |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −647−100.0% | Sold outConverted for a 1-for-30 split |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −337−100.0% | Sold outConverted for a 1-for-30 split |
| Welch Group, LLC | 0 | $0 | 0.00% | −333−100.0% | Sold outConverted for a 1-for-30 split |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −5−100.0% | Sold outConverted for a 1-for-30 split |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-30 split |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold outConverted for a 1-for-30 split |